IDiyas

For the Inventor, By the Inventor

Osaka, Japan

Kenji Fukunaga

USPTO Granted Patents = 18

 

Average Co-Inventor Count = 5.0

ph-index = 6

Forward Citations = 252(Granted Patents)


Location History:

  • Yokohama, JP (2006)
  • Kawasaki, JP (2010 - 2011)
  • Tokyo, JP (2005 - 2012)
  • Kanagawa, JP (2009 - 2013)
  • Kobe, JP (2017)
  • Osaka, JP (2000 - 2020)

Company Filing History:

goldMedal9 out of 257 
 
Mitsubishi Tanabe Pharma Corporation
 patents
silverMedal8 out of 39,228 
 
Fujitsu Corporation
 patents
bronzeMedal4 out of 389 
 
Sanofi-aventis
 patents
4. 3 out of 1,451 
 
Sanofi
 patents
5. 1 out of 73 
 
Mitsubishi Pharma Corporation
 patents
where one patent can have more than one assignee

Years Active: 2000-2020

Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents
1. 10793582 - Bicyclic heterocyclic compound (2020-10-06),
2. 10065972 - Bicyclic or tricyclic heterocyclic compound (2018-09-04),
3. 9735906 - Demultiplexing device and multiplexing device (2017-08-15),
4. 8592417 - 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors (2013-11-26),
5. 8569294 - 2-(cyclic amino)-pyrimidone derivatives (2013-10-29),
6. 8518939 - 6-pyrimidinyl-pyrimid-4-one derivative (2013-08-27),
7. 8198437 - 6-pyrimidinyl-pyrimid-4-one derivative (2012-06-12),
8. 8129377 - 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors (2012-03-06),
9. 8106045 - 2-morpholino-4-pyrimidone compound (2012-01-31),
10. 8086770 - Communication apparatus with data discard functions and control method therefor (2011-12-27),
11. 7907632 - Data output apparatus, communication apparatus and switch apparatus (2011-03-15),
12. 7706391 - Packet transmission method and device (2010-04-27),
13. 7504411 - 2,3,6-Trisubstituted-4-pyrimidone derivatives (2009-03-17),
14. 7359316 - Reception pointer processing apparatus in SDH transmission system (2008-04-15),
15. 7027459 - Transmission line terminating apparatus that performs packet processing (2006-04-11),

Title: Kenji Fukunaga: Innovator in Heterocyclic Compounds

Introduction

Kenji Fukunaga is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds. With a total of 18 patents to his name, Fukunaga's work has had a substantial impact on medicinal chemistry.

Latest Patents

Fukunaga's latest patents include a bicyclic heterocyclic compound that exhibits superior inhibitory action on KAT-II. This invention provides a novel compound, a production method, and a pharmaceutical composition containing the compound. Additionally, he has developed a bicyclic or tricyclic heterocyclic compound represented by a specific formula, which includes an optionally substituted aromatic group.

Career Highlights

Throughout his career, Kenji Fukunaga has worked with notable companies such as Mitsubishi Tanabe Pharma Corporation and Fujitsu Corporation. His expertise in the field has allowed him to contribute to various innovative projects and advancements in pharmaceutical research.

Collaborations

Fukunaga has collaborated with esteemed colleagues, including Kazutoshi Watanabe and Toshiyuki Kohara. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Kenji Fukunaga's contributions to the field of heterocyclic compounds and pharmaceuticals highlight his role as a leading inventor. His work continues to influence the development of new therapeutic agents, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…